Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.
As early as late January, Ke Wu believed there was an urgent need to develop a vaccine for a novel coronavirus that was spreading in the Chinese city of Wuhan, where his biotech company BravoVax is located.
After discussions, on 25 January BravoVax announced a collaboration with US company GeoVax Labs Inc. to develop a vaccine...